Clinical Trial Update: Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating the protective efficacy of a quadrivalent recombinant norovirus vaccine produced in Pichia pastoris for acute gastroenteritis due …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Gastroenteritis

Drugs mentioned

• Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) (Norovirus vaccine)

Snippet

Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Conditions: Acute Gastroenteropathy Due to Norovirus | Phase 3 | Status: ACTIVE_NOT_RECRUITING